FDA product code KKH: Tablet, Resazurin
KKH is the FDA product code for tablet, resazurin. It is a Class I device, regulated under 21 CFR 864.1850 and reviewed by the Pathology panel. Devices under KKH reach the market by 510(k) exempt; FDA lists no cleared 510(k)s for it. FDA has posted 1 recall for KKH devices, 1 initiated in the last five years.
Classification
| Field | Value |
|---|---|
| Device name | Tablet, Resazurin |
| Device class | Class I |
| Regulation | 21 CFR 864.1850 |
| Review panel | PA — Pathology |
| Medical specialty | Hematology |
| Premarket route | 510(k) exempt |
| GMP exempt | Yes |
Recalls for KKH devices
1 product recalls in 1 recall events; 1 initiated in the last five years and 1 still open. Most recent: 2022-05-25.
| Year | Recalls |
|---|---|
| 2022 | 1 |
Frequently asked questions
What is FDA product code KKH?
KKH is the FDA product code for tablet, resazurin. It is a Class I device, regulated under 21 CFR 864.1850 and reviewed by the Pathology panel.
What device class is KKH?
Class I, regulation 21 CFR 864.1850. Typical premarket route: 510(k) exempt.
Have KKH devices been recalled?
Yes: 1 product recalls across 1 recall events; the most recent began 2022-05-25.
Next steps
- Run an FDA pathway report with predicate devices for product code KKH
- Run a recall and safety report across every KKH manufacturer
- Watch product code KKH for new clearances and recalls
Source: openFDA device classification, 510(k), PMA, De Novo and recall data (public domain). Review days run from FDA receipt to decision. Not regulatory advice.
All Pathology product codes · FDA product code lookup · 510(k) database search · 510(k) review times